Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 3Vomiting 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Opioid-Related Disorders 1Neoplasms 1Nausea 1Lymphoma, Follicular 1Cancer Pain 1Breakthrough Pain 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Methadone × Clear all
NCT00125294 2017-09-25

Sublingual Methadone for the Management of Cancer Breakthrough Pain

AHS Cancer Control Alberta

Phase 1 Completed
10 enrolled

Cancer Pain, Neoplasms, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡